Public Citizen’s Health Group Changes Leadership, But Wolfe Remains On Prowl
Executive Summary
Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.
You may also be interested in...
Advocacy For Drug Safety And Public Health Loses Passionate And Effective Leader Sidney Wolfe
Wolfe is lauded by former colleagues for his fierceness in pushing to get dangerous drugs off the market, his rigorous scientific approach, and mastery of the press.
Sidney Wolfe, Iconic Advocate For Drug Safety, Dies At 86
Wolfe is lauded by former colleagues for his fierceness in pushing to get dangerous drugs off the market, his rigorous scientific approach, and mastery of the press.
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.